Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
AVTX Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AVTX Stock 12 Month Forecast
Average Price Target
$27.94
▲(212.88% Upside)
| Highest Price Target$48.00 | Average Price Target$27.94 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$15
Buy
67.97%
Upside
Reiterated
08/08/25
BTIG
$40
Buy
347.93%
Upside
Reiterated
08/07/25
Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy RatingWe also note that LOTUS is expected to involve HS-ABX non-responder criteria, consistent with MLTX's MIRA and VELA trials and in contrast to UCB's (Not Rated) BE HEARD I/II trials; possible implications for UCB discussed in detail below. Mgmt. plans to share LOTUS baseline characteristics data following enrollment completion and expects results to look similar to recent late-stage studies in HS. We see good odds for even better efficacy enabled by AVTX-009's core PK/PD advantages vs. lutikizumab, reviewed in detail HERE. That said, HS remains a large, under-penetrated market with high-growth potential (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s), where we see adequate room for multiple advanced therapies to coexist and be commercially successful.
Piper Sandler
$48
Buy
437.51%
Upside
Reiterated
07/28/25
Stifel Nicolaus
$36
Buy
303.14%
Upside
Reiterated
07/28/25
Jefferies
$23
Buy
157.56%
Upside
Initiated
03/25/25
Oppenheimer
$35
Buy
291.94%
Upside
Reiterated
03/24/25
Wedbush
$18
Buy
101.57%
Upside
Initiated
02/20/25
Lucid Capital
$24
Buy
168.76%
Upside
Initiated
12/17/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$15
Buy
67.97%
Upside
Reiterated
08/08/25
BTIG
$40
Buy
347.93%
Upside
Reiterated
08/07/25
Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy RatingWe also note that LOTUS is expected to involve HS-ABX non-responder criteria, consistent with MLTX's MIRA and VELA trials and in contrast to UCB's (Not Rated) BE HEARD I/II trials; possible implications for UCB discussed in detail below. Mgmt. plans to share LOTUS baseline characteristics data following enrollment completion and expects results to look similar to recent late-stage studies in HS. We see good odds for even better efficacy enabled by AVTX-009's core PK/PD advantages vs. lutikizumab, reviewed in detail HERE. That said, HS remains a large, under-penetrated market with high-growth potential (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s), where we see adequate room for multiple advanced therapies to coexist and be commercially successful.
Piper Sandler
$48
Buy
437.51%
Upside
Reiterated
07/28/25
Stifel Nicolaus
$36
Buy
303.14%
Upside
Reiterated
07/28/25
Jefferies
$23
Buy
157.56%
Upside
Initiated
03/25/25
Oppenheimer
$35
Buy
291.94%
Upside
Reiterated
03/24/25
Wedbush
$18
Buy
101.57%
Upside
Initiated
02/20/25
Lucid Capital
$24
Buy
168.76%
Upside
Initiated
12/17/24
Best Analysts Covering Avalo Therapeutics
1 Month
xxx
Success Rate
2/4 ratings generated profit
Average Return
-6.28%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -6.28% per trade.
3 Months
xxx
Success Rate
2/4 ratings generated profit
Average Return
+9.55%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.55% per trade.
1 Year
Success Rate
3/4 ratings generated profit
Average Return
+25.17%
reiterated a buy rating 5 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +25.17% per trade.
2 Years
xxx
Success Rate
3/4 ratings generated profit
Average Return
+25.17%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +25.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AVTX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
7
5
2
5
8
Buy
0
0
0
0
0
Hold
4
4
5
11
14
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
12
11
9
17
22
Each month's total comprises the sum of three months' worth of ratings.
AVTX Financial Forecast
AVTX Stock Forecast FAQ
What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics’s 12-month average price target is 27.94.
What is AVTX’s upside potential, based on the analysts’ average price target?
Avalo Therapeutics has 212.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVTX a Buy, Sell or Hold?
Avalo Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Avalo Therapeutics’s price target?
The average price target for Avalo Therapeutics is 27.94. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $9.00. The average price target represents 212.88% Increase from the current price of $8.93.
The highest analyst price target is $48.00 ,the lowest forecast is $9.00. The average price target represents 212.88% Increase from the current price of $8.93.
What do analysts say about Avalo Therapeutics?
Avalo Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of AVTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.